Skip to content
Boca Raton City Online – Lifestyle
Author:
Vor Biopharma
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
June 8, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
May 14, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
←
Previous Page
1
2